| Company Name: |
InvivoChem |
| Tel: |
+1-708-310-1919 +1-13798911105 |
| Email: |
sales@invivochem.cn |
| Company Name: |
InvivoChem |
| Tel: |
13549236410 |
| Email: |
sales@invivochem.cn |
|
| | INCB053914 Basic information |
| Product Name: | INCB053914 | | Synonyms: | INCB053914;Uzansertib (INCB053914);2-Pyridinecarboxamide, N-[(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methyl-1-piperidinyl]-6,7-dihydro-7-hydroxy-5H-cyclopenta[b]pyridin-3-yl]-6-(2,6-difluorophenyl)-5-fluoro-;Uzansertib | | CAS: | 1620012-39-6 | | MF: | C26H26F3N5O3 | | MW: | 513.51 | | EINECS: | | | Product Categories: | | | Mol File: | 1620012-39-6.mol |  |
| | INCB053914 Chemical Properties |
| Boiling point | 642.7±55.0 °C(Predicted) | | density | 1.444±0.06 g/cm3(Predicted) | | form | Solid | | pka | 3.09±0.40(Predicted) | | color | White to off-white |
| | INCB053914 Usage And Synthesis |
| Uses | Uzansertib (INCB053914) is an orally active, ATP-competitive pan-PIM kinase inhibitor with IC50s of 0.24 nM, 30 nM, 0.12 nM for PIM1, PIM2, PIM3, respectively. Uzansertib has broad anti-proliferative activity against a variety of hematologic tumor cell lines[1]. | | in vivo | Uzansertib (25-100 mg/kg; PO; twice a day; for 15 days) inhibits tumor growth in a dose-dependent manner in mice bearing MOLM-16 (AML) or KMS-12-BM (MM) [1].
Uzansertib demonstrates a dose-dependent inhibition of BAD phosphorylation relative to vehicle at 4 hours post dose (MOLM-16 tumors, IC50=70 nM; KMS-12-BM tumors, IC50=145 nM) [1].
| Animal Model: | Female immune compromised (severe combined immunodeficiency [SCID]) mice (5-9 weeks of age) bearing MOLM-16 (AML) or KMS-12-BM (MM)[1] | | Dosage: | 25, 50, 75, 100 mg/kg | | Administration: | PO; twice a day; for 15 days | | Result: | Inhibited tumor growth in a dose-dependent manner in mice.
|
| | IC 50 | PIM1: 0.24 nM (IC50); PIM2: 30 nM (IC50); PIM3: 0.12 nM (IC50) | | References | [1] Koblish H, et al. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies. PLoS One. 2018 Jun 21;13(6):e0199108. DOI:10.1371/journal.pone.0199108 |
| | INCB053914 Preparation Products And Raw materials |
|